Jump to content

MiR-132: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
m journal cites:, added 2 PMCs, using AWB (7630)
 
(36 intermediate revisions by 24 users not shown)
Line 1: Line 1:
{{Short description|Non-coding RNA molecule}}
⚫
{{Use dmy dates|date=July 2021}}
{{Infobox rfam
{{Infobox rfam
| Name = miR-132
| Name = miR-132
Line 15: Line 17:
}}
}}


In molecular biology '''miR-132 microRNA''' is a short [[non-coding RNA]] molecule. [[MicroRNA]]s function to regulate the expression levels of other genes by several mechanisms, generally reducing protein levels though the cleavage of mRNAs or the repression of their translation. Several targets for miR-132 have been described, including mediators of [[Neurogenesis|neurological development]], [[synaptic transmission]], [[inflammation]] and [[angiogenesis]].
In molecular biology '''miR-132 microRNA''' is a short [[non-coding RNA]] molecule. [[MicroRNA]]s function to regulate the expression levels of other genes by several mechanisms, generally reducing protein levels through the cleavage of mRNAs or the repression of their translation. Several targets for miR-132 have been described, including mediators of [[Neurogenesis|neurological development]], [[synaptic transmission]], [[inflammation]] and [[angiogenesis]].


==Expression==
==Expression==
miR-132 arises from the miR-212/132 cluster located in the intron of a non-coding gene on mouse chromosome 11. The transcription of this cluster was found to be enhanced by the transcription factor [[CREB]] (cAMP-response element binding protein). In neuronal cells [[BDNF]] (brain derived neurotrophic factor) is known to induce the transcription of this cluster; the pathway is thought to involve the BDNF-mediated activation of ERK1/2, which in turn activates MSK, another [[kinase]] enzyme. MSK-mediated phosphorylation of a serine residue on CREB may then enhance production of miR-132. MSK knockout mice still produce miR-132 in response to BDNF, but at a significantly lower level, indicating that there may be an alternative pathway operating.<ref name="pmid20307261">{{cite journal |author=Remenyi J, Hunter CJ, Cole C, Ando H, Impey S, Monk CE, Martin KJ, Barton GJ, Hutvagner G, Arthur JS |title=Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins |journal=Biochem J.|volume=428 |issue=2 |pages=281–91|year=2010 |pmid=20307261 |doi=10.1042/BJ20100024}}</ref> Activators of CREB phosphorylation, for instance [[forskolin]] and [[Kaposi's sarcoma-associated herpesvirus|KSHV]] binding to endothelial cell targets, can also enhance miR-132 production in vitro. miR-132 levels are increased post-seizure, which strongly suggests a causal relationship between neuronal activation and miR-132 transcription.<ref name="pmid19557767">{{cite journal |author=Nudelman AS, DiRocco DP, Lambert TJ, Garelick MG, Le J, Nathanson NM, Storm DR |title=Neuronal activity rapidly induces transcription of the CREB-regulated microRNA-132, in vivo |journal=Hippocampus |volume=20 |issue=4 |pages=492–8 |year=2010 |pmid=19557767 |doi=10.1002/hipo.20646}}</ref> One example of this phenomenon is in the [[suprachiasmatic nucleus]], where miR-132 is thought be involved in resetting the [[circadian clock]] in response to light.<ref name="pmid17553428">{{cite journal |author=Cheng HY, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, Nakazawa T, Shimizu K, Okamura H, Impey S, Obrietan K |title=microRNA modulation of circadian-clock period and entrainment |journal=Neuron |volume=54 |issue=5 |pages=813–29 |year=2007 |pmid=17553428 |doi=10.1016/j.neuron.2007.05.017}}</ref> Inflammatory mediators such as [[Lipopolysaccharide]] (LPS) are also implicated in inducing miR-132 expression.
miR-132 arises from the miR-212/132 cluster located in the intron of a non-coding gene on mouse chromosome 11. The transcription of this cluster was found to be enhanced by the transcription factor [[CREB]] (cAMP-response element binding protein). In neuronal cells [[BDNF]] (brain derived neurotrophic factor) is known to induce the transcription of this cluster; the pathway is thought to involve the BDNF-mediated activation of ERK1/2, which in turn activates MSK, another [[kinase]] enzyme. MSK-mediated phosphorylation of a serine residue on CREB may then enhance production of miR-132. MSK knockout mice still produce miR-132 in response to BDNF, but at a significantly lower level, indicating that there may be an alternative pathway operating.<ref name="pmid20307261">{{cite journal |vauthors=Remenyi J, Hunter CJ, Cole C, Ando H, Impey S, Monk CE, Martin KJ, Barton GJ, Hutvagner G, Arthur JS |title=Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins |journal=Biochem. J.|volume=428 |issue=2 |pages=281–91|year=2010 |pmid=20307261 |doi=10.1042/BJ20100024|url=https://hal.archives-ouvertes.fr/hal-00483250/file/PEER_stage2_10.1042%252FBJ20100024.pdf }}</ref> Activators of CREB phosphorylation, for instance [[forskolin]] and [[Kaposi's sarcoma-associated herpesvirus|KSHV]] binding to endothelial cell targets, can also enhance miR-132 production in vitro. miR-132 levels are increased post-seizure, which strongly suggests a causal relationship between neuronal activation and miR-132 transcription.<ref name="pmid19557767">{{cite journal |vauthors=Nudelman AS, DiRocco DP, Lambert TJ, Garelick MG, Le J, Nathanson NM, Storm DR |title=Neuronal activity rapidly induces transcription of the CREB-regulated microRNA-132, in vivo |journal=Hippocampus |volume=20 |issue=4 |pages=492–8 |year=2010 |pmid=19557767 |doi=10.1002/hipo.20646 |pmc=2847008}}</ref> One example of this phenomenon is in the [[suprachiasmatic nucleus]], where miR-132 is thought be involved in resetting the [[circadian clock]] in response to light.<ref name="pmid17553428">{{cite journal |vauthors=Cheng HY, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, Nakazawa T, Shimizu K, Okamura H, Impey S, Obrietan K |title=microRNA modulation of circadian-clock period and entrainment |journal=Neuron |volume=54 |issue=5 |pages=813–29 |year=2007 |pmid=17553428 |doi=10.1016/j.neuron.2007.05.017 |pmc=2590749}}</ref> Inflammatory mediators such as [[Lipopolysaccharide]] (LPS) are also implicated in inducing miR-132 expression.


==Role in neuronal cells==
==Role in neuronal cells==
miR-132 is enriched in neuronal cells. Recognition elements for this miRNA have been identified in a number of cellular mRNAs. One such mRNA is that of [[RICS (gene)|p250GAP]], a [[GTPase activating protein]] linked to neuronal differentiation. miR-132 and its recognition site on p250GAP mRNA are highly conserved among vertebrates, and their interaction is suspected to have a role in vertebrate [[neurogenesis]]. By decreasing the levels of p250GAP, miR-132 promotes neuronal outgrowth and sprouting.<ref name="pmid16260724 ">{{cite journal |author=Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S|title=A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis |journal=Proc Natl Acad Sci USA |volume=102 |issue=45 |pages=16426–31 |year=2005 |pmid=16260724 |doi=10.1073/pnas.0508448102 |pmc=1283476}}</ref>
miR-132 is enriched in neuronal cells. Recognition elements for this miRNA have been identified in a number of cellular mRNAs. One such mRNA is that of [[RICS (gene)|p250GAP]], a [[GTPase activating protein]] linked to neuronal differentiation. miR-132 and its recognition site on p250GAP mRNA are highly conserved among vertebrates, and their interaction is suspected to have a role in vertebrate [[neurogenesis]]. By decreasing the levels of p250GAP, miR-132 promotes neuronal outgrowth and sprouting.<ref name="pmid16260724 ">{{cite journal |vauthors=Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S |title=A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis |journal=Proc Natl Acad Sci USA |volume=102 |issue=45 |pages=16426–31 |year=2005 |pmid=16260724 |doi=10.1073/pnas.0508448102 |pmc=1283476|doi-access=free }}</ref>


Another target for miR-132 is [[MeCP2]], whose mRNA is expressed as a 'long' variant in neuronal cells. This variant contains a recognition element for miR-132 in its extended 3'UTR. miRNA-132 may be involved in a homeostatic mechanism that regulates MeCP2 levels in the brain. MeCP2 increases the levels of BDNF in the brain, which in turn will increase transcription from the miR-212/132 cluster. An rise in miRNA-132 level will then decrease the levels of MeCP2 and restore the balance. Failure to regulate MeCP2 levels is connected to neurological disorders including [[Rett syndrome]].<ref name="pmid17994015">{{cite journal |author=Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH|title=Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA|journal=Nat Neurosci |volume=10 |issue=12 |pages=1513–4|year=2007 |pmid=17994015 |doi=10.1038/nn2010}}</ref>
Another target for miR-132 is [[MeCP2]], whose mRNA is expressed as a 'long' variant in neuronal cells. This variant contains a recognition element for miR-132 in its extended 3'UTR. miRNA-132 may be involved in a homeostatic mechanism that regulates MeCP2 levels in the brain. MeCP2 increases the levels of BDNF in the brain, which in turn will increase transcription from the miR-212/132 cluster. A rise in miRNA-132 level will then decrease the levels of MeCP2 and restore the balance. Failure to regulate MeCP2 levels is connected to neurological disorders including [[Rett syndrome]].<ref name="pmid17994015">{{cite journal |vauthors=Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH |title=Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA|journal=Nat Neurosci |volume=10 |issue=12 |pages=1513–4|year=2007 |pmid=17994015 |doi=10.1038/nn2010|s2cid=29308441}}</ref>


The role of miR-132 in synaptic function is currently being studied. A BDNF-related increase in miR-132 is thought to bring about an increase in post-synaptic protein levels.<ref name="pmid19958814">{{cite journal |author=Kawashima H, Numakawa T, Kumamaru E, Adachi N, Mizuno H, Ninomiya M, Kunugi H, Hashido K |title=Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression |journal=Neuroscience |volume=165 |issue=4 |pages=1301–11 |year=2010 |pmid=19958814 |doi=10.1016/j.neuroscience.2009.11.057}}</ref> miR-132 has been found to associate with Fragile X Mental Retardation Protein [[FMRP]], and may be involved in the selection of mRNAs, including those regulating synaptic function, to undergo translational suppression via an FMRP-dependent mechansim.<ref name="pmid20159450">{{cite journal |author=Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, Tada T, Dolan BM, Sharp PA, Sheng M |title=Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132 |journal=Neuron |volume=65 |issue=3 |pages=373–84 |year=2010 |pmid=20159450 |doi=10.1016/j.neuron.2010.01.005}}</ref>
The role of miR-132 in synaptic function is currently being studied. A BDNF-related increase in miR-132 is thought to bring about an increase in post-synaptic protein levels.<ref name="pmid19958814">{{cite journal |vauthors=Kawashima H, Numakawa T, Kumamaru E, Adachi N, Mizuno H, Ninomiya M, Kunugi H, Hashido K |title=Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression |journal=Neuroscience |volume=165 |issue=4 |pages=1301–11 |year=2010 |pmid=19958814 |doi=10.1016/j.neuroscience.2009.11.057|s2cid=23619017 }}</ref> miR-132 has been found to associate with Fragile X Mental Retardation Protein [[FMRP]], and may be involved in the selection of mRNAs, including those regulating synaptic function, to undergo translational suppression via an FMRP-dependent mechanism.<ref name="pmid20159450">{{cite journal |vauthors=Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, Tada T, Dolan BM, Sharp PA, Sheng M |title=Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132 |journal=Neuron |volume=65 |issue=3 |pages=373–84 |year=2010 |pmid=20159450 |pmc=5018398 |doi=10.1016/j.neuron.2010.01.005}}</ref>


miR-132 may also be responsible for limiting inflammation in the brain. A recognition sequence for this miRNA can be found in the mRNA for [[acetylcholinesterase]] (AChE), that degrades [[acetylcholine]] (ACh). By silencing the expression of AChE, ACh levels rise and inhibit peripheral inflammation.<ref name="pmid20005135">{{cite journal |author=Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H |title=MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase|journal=Immunity |volume=31 |issue=6 |pages=965–73 |year=2009 |pmid=20005135 |doi=10.1016/j.immuni.2009.09.019}}</ref>
miR-132 may also be responsible for limiting inflammation in the brain. A recognition sequence for this miRNA can be found in the mRNA for [[acetylcholinesterase]] (AChE), that degrades [[acetylcholine]] (ACh). By silencing the expression of AChE, ACh levels rise and inhibit peripheral inflammation.<ref name="pmid20005135">{{cite journal |vauthors=Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H |title=MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase|journal=Immunity |volume=31 |issue=6 |pages=965–73 |year=2009 |pmid=20005135 |doi=10.1016/j.immuni.2009.09.019|doi-access=free }}</ref>


==Infection and inflammation==
==Infection and inflammation==
Outside the brain, miR-132 can also modulate inflammation; transcription is stimulated by LPS and upregulated at a fairly early stage of herpesvirus infection. [[Kaposi's sarcoma-associated herpesvirus|KSHV]] infection of endothelial cells, as well as [[HSV-1]] or [[HCMV]] infection of monocytes, have been observed to induce this rise. In this instance the target of translational suppression appears to be [[p300-CBP coactivator family|p300]], a protein that associates with CREB and is an important mediator of antiviral immunity. By decreasing the levels of p300, the expression of [[IFN-β]], [[ISG15]], [[IL1B|IL-1β]] and [[Interleukin 6|IL6]] is impaired, resulting in the net suppression of antiviral immunity. miR-132 is only transiently induced following infection; the silencing of p300 results in a reduction in CREB-mediated transcription from the miR-212/132 cluster, thus forming a negative feedback loop.<ref name="pmid20418869">{{cite journal |author=Lagos D, Pollara G, Henderson S, Gratrix F, Fabani M, Milne RS, Gotch F, Boshoff C |title=miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator |journal=Nat Cell Biol |volume=12 |issue=5 |pages=513–9 |year=2010 |pmid=20418869 |doi=10.1038/ncb2054}}</ref>
Outside the brain, miR-132 can also modulate inflammation; transcription is stimulated by LPS and upregulated at a fairly early stage of herpesvirus infection. [[Kaposi's sarcoma-associated herpesvirus|KSHV]] infection of endothelial cells, as well as [[HSV-1]] or [[HCMV]] infection of monocytes, have been observed to induce this rise. In this instance, the target of translational suppression appears to be [[p300-CBP coactivator family|p300]], a protein that associates with CREB and is an important mediator of antiviral immunity. By decreasing the levels of p300, the expression of [[IFN-β]], [[ISG15]], [[IL1B|IL-1β]] and [[Interleukin 6|IL6]] is impaired, resulting in the net suppression of antiviral immunity. miR-132 is only transiently induced following infection; the silencing of p300 results in a reduction in CREB-mediated transcription from the miR-212/132 cluster, thus forming a [[negative feedback]] loop.<ref name="pmid20418869">{{cite journal |vauthors=Lagos D, Pollara G, Henderson S, Gratrix F, Fabani M, Milne RS, Gotch F, Boshoff C |title=miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator |journal=Nat Cell Biol |volume=12 |issue=5 |pages=513–9 |year=2010 |pmid=20418869 |doi=10.1038/ncb2054|s2cid=26625810 }}</ref>


Plasma from patients with [[rheumatoid arthritis]] (RA) has been found to contain lower levels of miR-132 compared to samples from healthy individuals.<ref name="pmid20470394">{{cite journal |author=Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, Nakamura T |title=Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis |journal=Arthritis Res Ther|volume=12 |issue=3 |year=2010 |pmid=20470394 |doi=10.1186/ar3013 |pages=R86}}</ref> As RA is an autoimmune, inflammatory disease, it is possible that miR-132 helps to regulate inflammation in healthy joints.
Plasma from patients with [[rheumatoid arthritis]] (RA) has been found to contain lower levels of miR-132 compared to samples from healthy individuals.<ref name="pmid20470394">{{cite journal |vauthors=Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, Nakamura T |title=Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis |journal=[[Arthritis Research & Therapy]]|volume=12 |issue=3 |year=2010 |pmid=20470394 |doi=10.1186/ar3013 |pages=R86 |pmc=2911870 |doi-access=free }}</ref> As RA is an autoimmune, inflammatory disease, it is possible that miR-132 helps to regulate inflammation in healthy joints.


Conversely, miR-132 has been implicated in promoting inflammation in adipocytes. The target for RNA silencing in this case is [[Sirtuin 1|SirT1]], a [[acetylation|deacetylase]] enzyme. The p65 subunit of [[NF-κB]] is a SirT1 substrate; in the absence of SirT1 activity, NFκB is active, promoting inflammation and the production of the chemokines [[Interleukin 8|IL-8]] and [[MCP-1]]. This process is implicated in the chronic inflammation that may underly [[insulin resistance]] in the obese, and may occur in response to serum deprivation.<ref name="pmid19819989">{{cite journal |author=Strum JC, Johnson JH, Ward J, Xie H, Feild J, Hester A, Alford A, Waters KM |title=MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1 |journal=Mol Endocrinol |volume=23 |issue=11 |pages=1876–84 |year=2009 |pmid=19819989 |doi=10.1210/me.2009-0117}}</ref>
Conversely, miR-132 has been implicated in promoting inflammation in adipocytes. The target for RNA silencing in this case is [[Sirtuin 1|SirT1]], a [[acetylation|deacetylase]] enzyme. The p65 subunit of [[NF-κB]] is a SirT1 substrate; in the absence of SirT1 activity, NFκB is active, promoting inflammation and the production of the chemokines [[Interleukin 8|IL-8]] and [[MCP-1]]. This process is implicated in the chronic inflammation that may underlie [[insulin resistance]] in the obese, and may occur in response to serum deprivation.<ref name="pmid19819989">{{cite journal |vauthors=Strum JC, Johnson JH, Ward J, Xie H, Feild J, Hester A, Alford A, Waters KM |title=MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1 |journal=Mol Endocrinol |volume=23 |issue=11 |pages=1876–84 |year=2009 |pmid=19819989 |pmc=5419165 |doi=10.1210/me.2009-0117}}</ref>


==Angiogenesis and cancer==
==Angiogenesis and cancer==
miR-132 can induce the proliferation of endothelial cells and has been implicated in neovascularisation. [[Angiogenesis|Angiogenic]] factors such as [[VEGF]] and [[bFGF]] are CREB activators which could theoretically induce miR-132 production in endothelial cells. Here, the miRNA can silence the expression of [[RAS p21 protein activator 1|p120RasGAP]], fixing [[Ras superfamily|Ras]] in a GTP-bound, active conformation so as to induce proliferation.<ref name="pmid20676106">{{cite journal |author=Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh DA |title=MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis |journal=Nat Med |volume=16 |issue=8 |pages=909–14 |year=2010 |pmid=20676106 |doi=10.1038/nm.2186}}</ref> This angiogenic role could implicate miR-132 in oncogenesis, and this miRNA is known to be overexpressed in chronic lymphoblastic leukaemias.<ref name="pmid15284443">{{cite journal |author=Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM|title=MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias|journal=Proc Natl Acad Sci U S A. |volume=101 |issue=32 |pages=11755–60 |year=2004|pmid=15284443 |doi=10.1073/pnas.0404432101 |pmc=511048}}</ref> miR-132 also comprises part of the recently identified miRNA 'signature' of mammalian osteosarcoma, although a direct role in oncogenesis is yet to be fully described.<ref name="pmid20949564">{{cite journal |author=Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY, Alberti L|title=miRNA profiles in osteosarcoma as a predictive tool for ifosfamide response|journal=Int J Cancer|year=2010 |pmid=20949564|doi=10.1002/ijc.25715}}</ref>
miR-132 can induce the proliferation of endothelial cells and has been implicated in neovascularisation. [[Angiogenesis|Angiogenic]] factors such as [[VEGF]] and [[bFGF]] are CREB activators which could theoretically induce miR-132 production in endothelial cells. Here, the miRNA can silence the expression of [[RAS p21 protein activator 1|p120RasGAP]], fixing [[Ras superfamily|Ras]] in a GTP-bound, active conformation so as to induce proliferation.<ref name="pmid20676106">{{cite journal |vauthors=Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh DA |title=MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis |journal=Nat Med |volume=16 |issue=8 |pages=909–14 |year=2010 |pmid=20676106 |doi=10.1038/nm.2186 |pmc=3094020}}</ref> This angiogenic role could implicate miR-132 in oncogenesis, and this miRNA is known to be overexpressed in chronic lymphoblastic leukaemias.<ref name="pmid15284443">{{cite journal |vauthors=Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM |title=MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias|journal=Proc Natl Acad Sci U S A |volume=101 |issue=32 |pages=11755–60 |year=2004|pmid=15284443 |doi=10.1073/pnas.0404432101 |pmc=511048|bibcode=2004PNAS..10111755C|doi-access=free}}</ref> miR-132 also comprises part of the recently identified miRNA 'signature' of mammalian osteosarcoma, although a direct role in oncogenesis is yet to be fully described.<ref name="pmid20949564">{{cite journal |vauthors=Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY, Alberti L |title=miRNA profiles in osteosarcoma as a predictive tool for ifosfamide response|journal=Int J Cancer|year=2010 |pmid=20949564|doi=10.1002/ijc.25715|issue= 3|pages=680–690 |volume=129|doi-access=free}}</ref>

==Heart pathology==
MiR-132 has been found to inhibit cardiac pathology in rodents.<ref name=":0">{{Cite web | url=http://medicalxpress.com/news/2012-09-heart-failure-mice.html | title=Researchers prevent heart failure in mice}}</ref> Overactivation of miR-132 upon various cardiac stress provokes adverse [[Ventricular remodeling|remodeling]] of the heart tissue that is implicated in the development and progression of heart failure (HF). The inhibition of miR-132 is a valid strategy in the prevention of heart failure progression in hypertrophic heart disease.<ref>{{Cite journal |last1=Hinkel |first1=Rabea |last2=Batkai |first2=Sandor |last3=Bähr |first3=Andrea |last4=Bozoglu |first4=Tarik |last5=Straub |first5=Sarah |last6=Borchert |first6=Tobias |last7=Viereck |first7=Janika |last8=Howe |first8=Andrea |last9=Hornaschewitz |first9=Nadja |last10=Oberberger |first10=Lisa |last11=Jurisch |first11=Victoria |last12=Kozlik-Feldmann |first12=Rainer |last13=Freudenthal |first13=Franz |last14=Ziegler |first14=Tilman |last15=Weber |first15=Christian |title=AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction |journal=Journal of the American College of Cardiology |date=2021 |language=en |volume=77 |issue=23 |pages=2923–2935 |doi=10.1016/j.jacc.2021.04.028|doi-access=free }}</ref> [[CDR132L]] is the first-in-class synthetic antisense oligonucleotide inhibitor targeting miR-132, developed by [[Cardior Pharmaceuticals]] in the framework of the therapeutic strategy to bind abnormal levels of miR-132 to hold and reverse the development of detrimental cardiac remodeling. CDR132L is being currently investigated in a Phase 2 HF-REVERT Clinical Trial.<ref>[https://clinicaltrials.gov/ct2/show/NCT05350969</ref>


==Other targets==
==Other targets==
The [[Angiotensin II receptor type 1]] mRNA also undergoes miR-132-mediated silencing.<ref name="IDSN=389ON ">{{cite journal |author=Elton TS, Kuhn DE, Malana GE, Martin MM, Nuovo GJ, Pleister AP, Feldman DS |title=MiR-132 Regulates Angiotensin II Type 1 Receptor Expression Through a Protein Coding Region Binding Site|journal=Circulation|volume=118 |issue=18 |pages=S513|year=2007}}</ref>
The [[Angiotensin II receptor type 1]] mRNA also undergoes miR-132-mediated silencing.<ref name="IDSN=389ON ">{{cite journal |vauthors=Elton TS, Kuhn DE, Malana GE, Martin MM, Nuovo GJ, Pleister AP, Feldman DS |title=MiR-132 Regulates Angiotensin II Type 1 Receptor Expression Through a Protein Coding Region Binding Site|journal=Circulation|volume=118 |issue=18 |pages=S513|year=2007|url=http://circ.ahajournals.org/cgi/content/meeting_abstract/118/18_MeetingAbstracts/S_513}}</ref> [[KIAA1211L]] is also a predicted miR-132 target.<ref>{{Cite journal|last=Mooney|first=C.|date=2012|title=Prediction of Short Linear Protein Binding Receptors|journal=Journal of Molecular Biology|volume=415 | issue = 1 |pages=193–204|doi=10.1016/j.jmb.2011.10.025|pmid=22079048|hdl=10197/3395|hdl-access=free}}</ref>


== See also ==
== See also ==
Line 46: Line 51:


==References==
==References==
{{reflist|2}}
{{reflist}}
⚫
<!-- <ref name="pmid21059906">{{cite journal |vauthors=Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL, Mandel G, Goodman RH |title=microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus |journal=Proc Natl Acad Sci U S A |volume= 107|issue= 47|pages= 20382–7|year=2010 |pmid=21059906 |doi=10.1073/pnas.1015691107 |pmc=2996687}}</ref><ref name="pmid18075311">{{cite journal |vauthors=Cheng HY, Obrietan K |title=Revealing a role of microRNAs in the regulation of the biological clock |journal=Cell Cycle |volume=6 |issue=24 |pages=3034–5 |year=2007 |pmid=18075311 |doi=10.4161/cc.6.24.5106}}</ref><ref name="pmid19888283">{{cite journal |author=Schratt G|title=microRNAs at the synapse|journal=Nat Rev Neurosci|volume=10 |issue=12 |pages=842–9 |year=2009 |pmid=19888283 |doi=10.1038/nrn2763}}</ref><ref name="pmid20303342">{{cite journal |vauthors=Miller BH, Wahlestedt C |title=MicroRNA dysregulation in psychiatric disease|journal=Brain Res |pages=89–99 |year=2010 |pmid=20303342 |doi=10.1016/j.brainres.2010.03.035 |volume=1338 |pmc=2891055}}</ref><ref name="pmid20064444">{{cite journal |author=O'Neill LA |title=Boosting the brain's ability to block inflammation via microRNA-132 |journal=Immunity |volume=31 |issue=6 |pages=854–5 |year=2009 |pmid=20064444 |doi=10.1016/j.immuni.2009.11.004}}</ref> -->

==Further reading==
⚫
<div style='display:none'><ref name="pmid21059906">{{cite journal |author=Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL, Mandel G, Goodman RH |title=microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. |journal=Proc Natl Acad Sci U S A |volume= 107|issue= 47|pages= 20382–7|year=2010 |pmid=21059906 |doi=10.1073/pnas.1015691107}}</ref><ref name="pmid18075311">{{cite journal |author=Cheng HY, Obrietan K|title=Revealing a role of microRNAs in the regulation of the biological clock |journal=Cell Cycle |volume=6 |issue=24 |pages=3034–5 |year=2007 |pmid=18075311}}</ref><ref name="pmid19888283">{{cite journal |author=Schratt G|title=microRNAs at the synapse|journal=Nat Rev Neurosci|volume=10 |issue=12 |pages=842–9 |year=2009 |pmid=19888283 |doi=10.1038/nrn2763}}</ref><ref name="pmid20303342">{{cite journal |author=Miller BH, Wahlestedt C|title=MicroRNA dysregulation in psychiatric disease|journal=Brain Res |issue=1338 |pages=89–99 |year=2010 |pmid=20303342 |doi=10.1016/j.brainres.2010.03.035 |volume=1338}}</ref><ref name="pmid20064444">{{cite journal |author=O'Neill LA |title=Boosting the brain's ability to block inflammation via microRNA-132 |journal=Immunity |volume=31 |issue=6 |pages=854–5 |year=2009 |pmid=20064444 |doi=10.1016/j.immuni.2009.11.004}}</ref>
</div>

{{reflist|2}}


==External links==
==External links==
* {{Rfam|id=RF00662|name=mir-132 microRNA precursor family}}
* {{Rfam|id=RF00662|name=mir-132 microRNA precursor family}}

⚫
{{Use dmy dates|date=January 2011}}
{{miRNA precursor families}}


[[Category:MicroRNA]]
[[Category:MicroRNA]]

Latest revision as of 20:53, 1 November 2024

miR-132
miR-132 microRNA precursor secondary structure and sequence conservation.
Identifiers
SymbolmiR-132
RfamRF00662
miRBase familyMIPF0000065
NCBI Gene406921
HGNC31516
OMIM610016
Other data
RNA typemicroRNA
Domain(s)Eukaryota;
PDB structuresPDBe

In molecular biology miR-132 microRNA is a short non-coding RNA molecule. MicroRNAs function to regulate the expression levels of other genes by several mechanisms, generally reducing protein levels through the cleavage of mRNAs or the repression of their translation. Several targets for miR-132 have been described, including mediators of neurological development, synaptic transmission, inflammation and angiogenesis.

Expression

[edit]

miR-132 arises from the miR-212/132 cluster located in the intron of a non-coding gene on mouse chromosome 11. The transcription of this cluster was found to be enhanced by the transcription factor CREB (cAMP-response element binding protein). In neuronal cells BDNF (brain derived neurotrophic factor) is known to induce the transcription of this cluster; the pathway is thought to involve the BDNF-mediated activation of ERK1/2, which in turn activates MSK, another kinase enzyme. MSK-mediated phosphorylation of a serine residue on CREB may then enhance production of miR-132. MSK knockout mice still produce miR-132 in response to BDNF, but at a significantly lower level, indicating that there may be an alternative pathway operating.[1] Activators of CREB phosphorylation, for instance forskolin and KSHV binding to endothelial cell targets, can also enhance miR-132 production in vitro. miR-132 levels are increased post-seizure, which strongly suggests a causal relationship between neuronal activation and miR-132 transcription.[2] One example of this phenomenon is in the suprachiasmatic nucleus, where miR-132 is thought be involved in resetting the circadian clock in response to light.[3] Inflammatory mediators such as Lipopolysaccharide (LPS) are also implicated in inducing miR-132 expression.

Role in neuronal cells

[edit]

miR-132 is enriched in neuronal cells. Recognition elements for this miRNA have been identified in a number of cellular mRNAs. One such mRNA is that of p250GAP, a GTPase activating protein linked to neuronal differentiation. miR-132 and its recognition site on p250GAP mRNA are highly conserved among vertebrates, and their interaction is suspected to have a role in vertebrate neurogenesis. By decreasing the levels of p250GAP, miR-132 promotes neuronal outgrowth and sprouting.[4]

Another target for miR-132 is MeCP2, whose mRNA is expressed as a 'long' variant in neuronal cells. This variant contains a recognition element for miR-132 in its extended 3'UTR. miRNA-132 may be involved in a homeostatic mechanism that regulates MeCP2 levels in the brain. MeCP2 increases the levels of BDNF in the brain, which in turn will increase transcription from the miR-212/132 cluster. A rise in miRNA-132 level will then decrease the levels of MeCP2 and restore the balance. Failure to regulate MeCP2 levels is connected to neurological disorders including Rett syndrome.[5]

The role of miR-132 in synaptic function is currently being studied. A BDNF-related increase in miR-132 is thought to bring about an increase in post-synaptic protein levels.[6] miR-132 has been found to associate with Fragile X Mental Retardation Protein FMRP, and may be involved in the selection of mRNAs, including those regulating synaptic function, to undergo translational suppression via an FMRP-dependent mechanism.[7]

miR-132 may also be responsible for limiting inflammation in the brain. A recognition sequence for this miRNA can be found in the mRNA for acetylcholinesterase (AChE), that degrades acetylcholine (ACh). By silencing the expression of AChE, ACh levels rise and inhibit peripheral inflammation.[8]

Infection and inflammation

[edit]

Outside the brain, miR-132 can also modulate inflammation; transcription is stimulated by LPS and upregulated at a fairly early stage of herpesvirus infection. KSHV infection of endothelial cells, as well as HSV-1 or HCMV infection of monocytes, have been observed to induce this rise. In this instance, the target of translational suppression appears to be p300, a protein that associates with CREB and is an important mediator of antiviral immunity. By decreasing the levels of p300, the expression of IFN-β, ISG15, IL-1β and IL6 is impaired, resulting in the net suppression of antiviral immunity. miR-132 is only transiently induced following infection; the silencing of p300 results in a reduction in CREB-mediated transcription from the miR-212/132 cluster, thus forming a negative feedback loop.[9]

Plasma from patients with rheumatoid arthritis (RA) has been found to contain lower levels of miR-132 compared to samples from healthy individuals.[10] As RA is an autoimmune, inflammatory disease, it is possible that miR-132 helps to regulate inflammation in healthy joints.

Conversely, miR-132 has been implicated in promoting inflammation in adipocytes. The target for RNA silencing in this case is SirT1, a deacetylase enzyme. The p65 subunit of NF-κB is a SirT1 substrate; in the absence of SirT1 activity, NFκB is active, promoting inflammation and the production of the chemokines IL-8 and MCP-1. This process is implicated in the chronic inflammation that may underlie insulin resistance in the obese, and may occur in response to serum deprivation.[11]

Angiogenesis and cancer

[edit]

miR-132 can induce the proliferation of endothelial cells and has been implicated in neovascularisation. Angiogenic factors such as VEGF and bFGF are CREB activators which could theoretically induce miR-132 production in endothelial cells. Here, the miRNA can silence the expression of p120RasGAP, fixing Ras in a GTP-bound, active conformation so as to induce proliferation.[12] This angiogenic role could implicate miR-132 in oncogenesis, and this miRNA is known to be overexpressed in chronic lymphoblastic leukaemias.[13] miR-132 also comprises part of the recently identified miRNA 'signature' of mammalian osteosarcoma, although a direct role in oncogenesis is yet to be fully described.[14]

Heart pathology

[edit]

MiR-132 has been found to inhibit cardiac pathology in rodents.[15] Overactivation of miR-132 upon various cardiac stress provokes adverse remodeling of the heart tissue that is implicated in the development and progression of heart failure (HF). The inhibition of miR-132 is a valid strategy in the prevention of heart failure progression in hypertrophic heart disease.[16] CDR132L is the first-in-class synthetic antisense oligonucleotide inhibitor targeting miR-132, developed by Cardior Pharmaceuticals in the framework of the therapeutic strategy to bind abnormal levels of miR-132 to hold and reverse the development of detrimental cardiac remodeling. CDR132L is being currently investigated in a Phase 2 HF-REVERT Clinical Trial.[17]

Other targets

[edit]

The Angiotensin II receptor type 1 mRNA also undergoes miR-132-mediated silencing.[18] KIAA1211L is also a predicted miR-132 target.[19]

See also

[edit]

References

[edit]
  1. ^ Remenyi J, Hunter CJ, Cole C, Ando H, Impey S, Monk CE, Martin KJ, Barton GJ, Hutvagner G, Arthur JS (2010). "Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins" (PDF). Biochem. J. 428 (2): 281–91. doi:10.1042/BJ20100024. PMID 20307261.
  2. ^ Nudelman AS, DiRocco DP, Lambert TJ, Garelick MG, Le J, Nathanson NM, Storm DR (2010). "Neuronal activity rapidly induces transcription of the CREB-regulated microRNA-132, in vivo". Hippocampus. 20 (4): 492–8. doi:10.1002/hipo.20646. PMC 2847008. PMID 19557767.
  3. ^ Cheng HY, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, Nakazawa T, Shimizu K, Okamura H, Impey S, Obrietan K (2007). "microRNA modulation of circadian-clock period and entrainment". Neuron. 54 (5): 813–29. doi:10.1016/j.neuron.2007.05.017. PMC 2590749. PMID 17553428.
  4. ^ Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S (2005). "A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis". Proc Natl Acad Sci USA. 102 (45): 16426–31. doi:10.1073/pnas.0508448102. PMC 1283476. PMID 16260724.
  5. ^ Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH (2007). "Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA". Nat Neurosci. 10 (12): 1513–4. doi:10.1038/nn2010. PMID 17994015. S2CID 29308441.
  6. ^ Kawashima H, Numakawa T, Kumamaru E, Adachi N, Mizuno H, Ninomiya M, Kunugi H, Hashido K (2010). "Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression". Neuroscience. 165 (4): 1301–11. doi:10.1016/j.neuroscience.2009.11.057. PMID 19958814. S2CID 23619017.
  7. ^ Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, Tada T, Dolan BM, Sharp PA, Sheng M (2010). "Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132". Neuron. 65 (3): 373–84. doi:10.1016/j.neuron.2010.01.005. PMC 5018398. PMID 20159450.
  8. ^ Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H (2009). "MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase". Immunity. 31 (6): 965–73. doi:10.1016/j.immuni.2009.09.019. PMID 20005135.
  9. ^ Lagos D, Pollara G, Henderson S, Gratrix F, Fabani M, Milne RS, Gotch F, Boshoff C (2010). "miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator". Nat Cell Biol. 12 (5): 513–9. doi:10.1038/ncb2054. PMID 20418869. S2CID 26625810.
  10. ^ Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, Nakamura T (2010). "Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis". Arthritis Research & Therapy. 12 (3): R86. doi:10.1186/ar3013. PMC 2911870. PMID 20470394.
  11. ^ Strum JC, Johnson JH, Ward J, Xie H, Feild J, Hester A, Alford A, Waters KM (2009). "MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1". Mol Endocrinol. 23 (11): 1876–84. doi:10.1210/me.2009-0117. PMC 5419165. PMID 19819989.
  12. ^ Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh DA (2010). "MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis". Nat Med. 16 (8): 909–14. doi:10.1038/nm.2186. PMC 3094020. PMID 20676106.
  13. ^ Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM (2004). "MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias". Proc Natl Acad Sci U S A. 101 (32): 11755–60. Bibcode:2004PNAS..10111755C. doi:10.1073/pnas.0404432101. PMC 511048. PMID 15284443.
  14. ^ Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY, Alberti L (2010). "miRNA profiles in osteosarcoma as a predictive tool for ifosfamide response". Int J Cancer. 129 (3): 680–690. doi:10.1002/ijc.25715. PMID 20949564.
  15. ^ "Researchers prevent heart failure in mice".
  16. ^ Hinkel, Rabea; Batkai, Sandor; Bähr, Andrea; Bozoglu, Tarik; Straub, Sarah; Borchert, Tobias; Viereck, Janika; Howe, Andrea; Hornaschewitz, Nadja; Oberberger, Lisa; Jurisch, Victoria; Kozlik-Feldmann, Rainer; Freudenthal, Franz; Ziegler, Tilman; Weber, Christian (2021). "AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction". Journal of the American College of Cardiology. 77 (23): 2923–2935. doi:10.1016/j.jacc.2021.04.028.
  17. ^ [https://clinicaltrials.gov/ct2/show/NCT05350969
  18. ^ Elton TS, Kuhn DE, Malana GE, Martin MM, Nuovo GJ, Pleister AP, Feldman DS (2007). "MiR-132 Regulates Angiotensin II Type 1 Receptor Expression Through a Protein Coding Region Binding Site". Circulation. 118 (18): S513.
  19. ^ Mooney, C. (2012). "Prediction of Short Linear Protein Binding Receptors". Journal of Molecular Biology. 415 (1): 193–204. doi:10.1016/j.jmb.2011.10.025. hdl:10197/3395. PMID 22079048.
[edit]


Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=MiR-132&oldid=1254817461"